Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.85−0.15 (-5.15%)
Close on Nov 18, 2026Market cap $304.54MP/E –Yield –
Relmada Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Relmada Therapeutics's price to book ratio was 2.3× on Nov 11, 2026, against 15.8× a year earlier. Over the last 5 years it ranged from 0.0× to 16.9×, with a median of 1.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.3× | −14.6 |
| 2025 | Dec 31, 2025 | 16.9× | +16.6 |
| 2024 | Dec 31, 2024 | 0.3× | −0.9 |
| 2023 | Dec 29, 2023 | 1.2× | +1.2 |
| 2022 | Dec 30, 2022 | 0.0× | −5.4 |
| 2021 | Dec 31, 2021 | 5.4× | −35.6 |
| 2020 | Dec 31, 2020 | 41.0× | −8.9 |
| 2019 | Dec 31, 2019 | 49.9× | +24.5 |
| 2018 | Apr 30, 2018 | 25.4× | +19.0 |
| 2017 | Dec 29, 2017 | 6.4× | +4.1 |
| 2016 | Dec 30, 2016 | 2.4× | +0.4 |
| 2015 | Dec 31, 2015 | 2.0× | – |
See a number that looks wrong?